Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Open-Label, Uncontrolled, Multiple Dose Escalation, Cohort Expansion Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of ASN002 In Relapsed/Refractory Lymphoma, Myelofibrosis, Chronic Lymphocytic Leukemia, And Advanced Solid Tumors

Next Previous
Trial Profile

A Phase 1/2, Open-Label, Uncontrolled, Multiple Dose Escalation, Cohort Expansion Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of ASN002 In Relapsed/Refractory Lymphoma, Myelofibrosis, Chronic Lymphocytic Leukemia, And Advanced Solid Tumors

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 08 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gusacitinib (Primary)
  • Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Diffuse lymphoma; Follicular lymphoma; Large cell carcinoma; Lymphoma; Mantle-cell lymphoma; Myelofibrosis; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; Solid tumours
  • Focus Therapeutic Use
  • Sponsors Asana BioSciences; Kirilys Therapeutics

Most Recent Events

  • 13 Aug 2018 Status changed from recruiting to discontinued as per business decision.
  • 05 Jun 2018 Results (n=46) assessing safety, tolerability, pharmacokinetics, serum markers of inflammation, and response presented at the 54th Annual Meeting of the American Society of Clinical Oncology
  • 23 Jan 2018 Planned End Date changed from 1 May 2018 to 1 May 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top